Floatz logo

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril

Vulvar Carcinoma

Emory UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Vulvar Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2CCC
Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457
M.D. Anderson Cancer Center
Phase 2CCC

View all 19 →

Same molecule, other indications

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril is also rated in:

cerebral infarctionDormant
BBB
Indicative ·
79 / 100
View asset →
transient ischemic attackDormant
BBB
Indicative ·
75 / 100
View asset →
ischemic strokeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →